drugset / Trial / NCT02197273

Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)

NCT02197273

Completed 211 enrolled OhioHealth
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total joint arthroplasty, as compared to standard of care analgesia.

Timeline

Start
2014-07
Primary completion
2015-09
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified 266 mg Other
Background Bupivacaine Other / unclassified 0.25 % Intrathecal
Background Bupivacaine Other / unclassified 0.5 % Intrathecal
Background Bupivacaine Other / unclassified 15 ml Intrathecal
Background Bupivacaine Other / unclassified 30 ml Intrathecal
Background Epinephrine Other / unclassified Other
Background Fentanyl Other / unclassified Intrathecal
Background Methylprednisolone Other / unclassified 40 mg Other
Background Morphine Other / unclassified 10 mg Other
Background Ropivacaine Other / unclassified Other